ArticleBlood cancer discovery2021

Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis.

Victoria E Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.